+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma



VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma



Neurology 84(18): 1906-1908




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059225547

Download citation: RISBibTeXText

PMID: 25862796

DOI: 10.1212/wnl.0000000000001543


Related references

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. Bmc Cancer 18(1): 553, 2018

Is VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology 79(2): 103-111, 2012

Balance between angiogenic and anti-angiogenic isoforms of VEGF-A is associated with the complexity and severity of coronary artery disease. Clinica Chimica Acta; International Journal of Clinical Chemistry 478: 114-119, 2018

Balance between angiogenic and anti-angiogenic isoforms of VEGF-A is associated with the complexity and severity of coronary artery disease. Clinica Chimica Acta 478: 114-119, 2018

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. Journal of Biological Chemistry 285(8): 5532-5540, 2010

Atnt-08Cb-017: A Phase 1/2 Trial Of Bevacizumab Plus Tpi 287, A Novel Brain Penetrable Anti-Microtubule Agent, In Patients With Recurrent Glioblastoma NaVe To Anti-Angiogenic Therapy. Neuro-Oncology 17(Suppl 5): v11.4-v12, 2015

Atct-15Cb-018: A Phase 2 Trial Of Bevacizumab Plus Tpi 287, A Novel Brain Penetrable Anti-Microtubule Agent, In Patients With Recurrent Glioblastoma Following Progression On Anti-Angiogenic Therapy. Neuro-Oncology 17(Suppl 5): v4.3-v4, 2015

Dres-08. ANovel Xenograft Model Reveals AGene Cascade And Serum Biomarker Defining AMesenchymal Transition During The Evolution Of Glioblastoma Resistance To Anti-Angiogenic Therapy. Neuro-Oncology 19(Suppl_6): vi65, 2017

The anti-angiogenic isoforms of VEGF in health and disease. Biochemical Society Transactions 37(Pt 6): 1207-1213, 2010

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro-Oncology 15(7): 936-944, 2014

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale. Plos One 7(5): E35231, 2012

VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. Journal of Cancer Research and Clinical Oncology 138(3): 363-370, 2012

Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. Chemical Science 2011(2): 273-278, 2011

Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. Aaps Journal 14(3): 500-509, 2012

Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Molecular Therapy 12(4): 716-724, 2005